Ras family genes: An interesting link between cell cycle and cancer

Journal of Cellular Physiology

Volumn 192, Issue 2, 2002, Pages 125-130

  Macaluso, M ^a,b,d   Russo, G ^a,c   Cinti, C ^c   Bazan, V ^b   Gebbia, N ^b   Russo, A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; RAS PROTEIN;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; MULTIGENE FAMILY; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; HUMANS; NEOPLASMS; RAS PROTEINS;

EID: 0036303748     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10109     Document Type: Review

References (59)

1. A phase I trials of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabina in patients with advances cancer
2. Ras links growth factor signaling to the cell cycle machinery via regulatin of cyclin D1 and Cdk inhibitor p27KIP1
3. Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells
4. RAS and leukemia: From basis mechanisms to gene-directed therapy
5. The structural basis of the activation of RAS by SOS
6. Ras oncogenes in human cancer: A review
7. Prevalence of ras gene mutations in human colorectal cancers
8. Protein isoprenylation and methylation at carboxylterminal cysteine residues
9. Fibronectin, integrins, and growth control
10. Three-dimensional structure of an oncogenic protein: Catalytic domain of human c-H-ras p21
11. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, and methylphosphonathe oligonucleotides in nude mice
12. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta
13. Ras signalling and apoptosis
14. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway
15. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis
16. Ha-ras oncogenes are activated by somatic alterations in human urinary tracts tumours
17. Multiple ras effectors pathways contribute to G(1) progression
18. Kip1 accumulation during the cell cycle
19. Ras-dependent cell cycle commitment during G2 phase
20. Diacylglycerols and phosphatidates: Which molecular species are intracellular messengers?
21. Cell cycle targets of Ras/Raf signaling
22. Three-dimensional structures of H-ras p21 mutant: Molecular basis for their inability to function as signal switch molecules
23. Proteoglycans of the extracellular matrix in growth control
24. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway
25. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells
26. Ras versus cyclin-dependent kinase inhibitors
27. Function and regulation of Ras
28. Requirement of NF-kB activation to suppress p53-independent apoptosis induced by oncogenic RAS
29. Interactions of c-Raf-1 with phosphatidylserine and 14-3-3
30. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
31. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
32. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women
33. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
34. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinases inhibitor p27
35. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer
36. Developmentally-regulated expression of murine K-ras isoforms
37. Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells
38. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
39. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
40. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
41. GTPase-activating proteins. Helping hands to complement an active site
42. Blockade of the MAP kinase pathway suppresses growth of colon tumours in vivo
43. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1
44. Transformation of NIH/3T3 cells by mictoinjection of Ha-ras p21 protein
45. Fusion of the MLL gene with two different genes, AF-6 and AF-5alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia
46. Cell cycle-dependent activation of Ras
47. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity
48. Identification of Nore1 as a potential Ras effector
49. Preferential and novel activation of H-ras in human bladder carcinomas
50. Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors
51. Ets transcription factor: Nuclear effectors of the RAS-MAP-kinase signaling pathway
52. Identification of Ce-AF-6, a novel Caenorhabditis elegans protein, as a putative Ras effector
53. Caught in the act of the switch-on
54. Ras-effector interactions, the problem of specificity
55. Ras caught in another affair: The exchange factors for Ral
56. Biological effects of cRaf1 kinase inhibitors
57. Raf-induced prolifration or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1
58. The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells